1. Home
  2. LYRA vs VVOS Comparison

LYRA vs VVOS Comparison

Compare LYRA & VVOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LYRA
  • VVOS
  • Stock Information
  • Founded
  • LYRA 2005
  • VVOS 2016
  • Country
  • LYRA United States
  • VVOS United States
  • Employees
  • LYRA N/A
  • VVOS N/A
  • Industry
  • LYRA Medical/Dental Instruments
  • VVOS Medical Specialities
  • Sector
  • LYRA Health Care
  • VVOS Health Care
  • Exchange
  • LYRA Nasdaq
  • VVOS Nasdaq
  • Market Cap
  • LYRA 15.0M
  • VVOS 14.8M
  • IPO Year
  • LYRA 2020
  • VVOS 2020
  • Fundamental
  • Price
  • LYRA $9.40
  • VVOS $3.28
  • Analyst Decision
  • LYRA Buy
  • VVOS Strong Buy
  • Analyst Count
  • LYRA 2
  • VVOS 2
  • Target Price
  • LYRA $16.00
  • VVOS $6.10
  • AVG Volume (30 Days)
  • LYRA 1.9M
  • VVOS 236.5K
  • Earning Date
  • LYRA 08-13-2025
  • VVOS 08-13-2025
  • Dividend Yield
  • LYRA N/A
  • VVOS N/A
  • EPS Growth
  • LYRA N/A
  • VVOS N/A
  • EPS
  • LYRA N/A
  • VVOS N/A
  • Revenue
  • LYRA $1,185,000.00
  • VVOS $14,628,000.00
  • Revenue This Year
  • LYRA N/A
  • VVOS $17.40
  • Revenue Next Year
  • LYRA $1,286.17
  • VVOS $10.78
  • P/E Ratio
  • LYRA N/A
  • VVOS N/A
  • Revenue Growth
  • LYRA N/A
  • VVOS 9.47
  • 52 Week Low
  • LYRA $3.81
  • VVOS $1.97
  • 52 Week High
  • LYRA $37.50
  • VVOS $6.28
  • Technical
  • Relative Strength Index (RSI)
  • LYRA 45.31
  • VVOS 70.72
  • Support Level
  • LYRA $10.15
  • VVOS $2.03
  • Resistance Level
  • LYRA $14.88
  • VVOS $3.91
  • Average True Range (ATR)
  • LYRA 2.03
  • VVOS 0.26
  • MACD
  • LYRA -0.67
  • VVOS 0.13
  • Stochastic Oscillator
  • LYRA 0.42
  • VVOS 66.49

About LYRA Lyra Therapeutics Inc.

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

About VVOS Vivos Therapeutics Inc.

Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.

Share on Social Networks: